Stanley-Laman Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Stanley-Laman Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	-$242K	–	260
2020 Q4	$242K	Hold	500	–	–	0.04%	225
2020 Q3	$280K	Buy	+500	New	+$303K	0.06%	208
2019 Q3	–	Sell	-757	Closed	-$237K	–	276
2019 Q2	$237K	Buy	+757	New	+$252K	0.06%	254
2017 Q1	–	Sell	-2,977	Closed	-$1.09M	–	275
2016 Q4	$1.09M	Buy	2,977 +934	+46%	+$355K	0.34%	109
2016 Q3	$821K	Sell	2,043 -39	-2%	-$15.6K	0.34%	107
2016 Q2	$727K	Buy	+2,082	New	+$802K	0.28%	136

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stanley-Laman Group's REGN Position: Q1 2021 in Review

Stanley-Laman Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 500 shares — an estimated $242K sold.

Stanley-Laman Group first reported a position in REGN in Q2 2016 and held it in 6 quarters. The position peaked at $1.09M in Q4 2016. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Stanley-Laman Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Stanley-Laman Group sold 500 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $242K.
Stanley-Laman Group first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 6 quarters.
Stanley-Laman Group's Regeneron Pharmaceuticals position peaked at $1.09M in Q4 2016.
924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Stanley-Laman Group's 13F filing for Q1 2021, filed 5 May 2021.